Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
16 begutachtete Studien
Was die Evidenz sagt
Die meisten Studien zu Feverfew sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen randomisierten Studien, veröffentlicht 1985–2025 mit einer typischen Studiengröße von 82 Teilnehmenden.
Basierend auf 16 Studien · 4 RCTs · 1,053 Teilnehmende insgesamt
Konfidenz
Mittlere KonfidenzNach Outcome
4 Studien in den letzten 5 Jahren
A Cochrane review found insufficient consistent evidence to confirm feverfew's efficacy for migraine prevention, though some trials were positive.
Pittler MH et al. · The Cochrane database of systematic reviews (2000)
MIG-99 failed to show a significant migraine prophylactic effect in general. Accordingly, in the ITT analysis a dose-response relationship could not be observed. MIG-99 was shown to be effective only in a small predefined subgroup of patients with at least four attacks during the 28-day baseline period.
Pfaffenrath V et al. · Cephalalgia : an international journal of headache (2002)
Alternative agents, including feverfew, magnesium, and melatonin, have shown effectiveness and are generally well tolerated.
Moreland P, Gaffney B, Lanham JS. · American family physician (2025)
Feverfew may offer modest benefits in migraine prevention, warranting further high-quality, large-scale RCTs with standardised protocols.
Nelaturi V, Viswanatha GL, Shenoy RR, Khanna S, Krishnadas N. · Natural product research (2025)
Additionally, the safety, toxicity, and potential adverse effects of feverfew are comprehensively evaluated, with an overarching goal of providing valuable insights into the plant's potential for targeted and effective treatments.
Kashkooe A, Jalali A, Zarshenas MM, Hamedi A. · Biomedicines (2024)
Systematic reviews/meta-analyses suggest preliminary or satisfactory clinical evidence for... feverfew (Tanacetum partenium) for migraine prevention... However, firm conclusions of efficacy cannot be generally drawn.
Izzo AA et al. · Phytotherapy research : PTR (2016)
A systematic review found favorable but not definitive evidence for feverfew in migraine prophylaxis.
Saranitzky E et al. · Journal of dietary supplements (2009)
A landmark randomized, placebo-controlled trial found feverfew reduced the frequency and severity of migraine.
Murphy JJ et al. · Lancet (London, England) (1988)
An update on feverfew's efficacy and safety reported promising but inconclusive migraine data.
Ernst E et al. · Public health nutrition (2000)
Attack frequency was reduced by 57.2% at 6 weeks (p < 0.029) and by 61.7% at 12 weeks (p < 0.025) in nine of ten patients, with 70% patients having a reduction of at least 50%.
Shrivastava R et al. · Clinical drug investigation (2006)
An early systematic review found feverfew more effective than placebo in most, but not all, trials.
Vogler BK et al. · Cephalalgia : an international journal of headache (1998)
Conclusions The results provide preliminary evidence that VM symptom frequency and severity can be reduced by using nonprescription therapies.
Hannigan IP, Rosengren SM, Di Tanna GL, Watson SRD, Welgampola MS. · Internal medicine journal (2024)
An early controlled trial reported fewer migraines with feverfew.
Johnson ES et al. · British medical journal (Clinical research ed.) (1985)
A combination of riboflavin, magnesium, and feverfew was studied for migraine prophylaxis.
Maizels M et al. · Headache (2004)
our results indicate that PD-Feverfew extracts have potent anti-inflammatory activity suggesting that this botanical would be efficacious in relieving inflammation without inducing immune sensitization.
Sur R et al. · Inflammopharmacology (2009)
A phase I dose-escalation study established tolerability of standardized parthenolide doses of feverfew.
Curry EA 3rd et al. · Investigational new drugs (2004)